NeoGenomics, Inc. Deferred Income Tax Expense (Benefit)
NeoGenomics, Inc. (NEO) reported Deferred Income Tax Expense (Benefit) of -$3.11 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-17
- NeoGenomics, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$3.11M.
- NeoGenomics, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$2.57M.
- NeoGenomics, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$9.52M.
- NeoGenomics, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$15.24M.
| Period end | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$3.11M 10-K · filed 2026-02-17 | |
| 2024-12-31 | -$2.57M 10-K · filed 2026-02-17 | |
| 2023-12-31 | -$9.52M 10-K · filed 2026-02-17 | |
| 2022-12-31 | -$15.24M 10-K · filed 2025-02-18 | |
| 2021-12-31 | -$6.81M 10-K · filed 2024-02-20 | |
| 2020-12-31 | -$18.07M 10-K · filed 2023-02-24 | |
| 2019-12-31 | -$4.35M 10-K · filed 2022-02-25 | |
| 2018-12-31 | $1.51M 10-K · filed 2021-02-25 | |
| 2017-12-31 | -$2.18M 10-K · filed 2020-02-28 | -$2.56M 10-K · filed 2018-03-13 |
| 2016-12-31 | -$1.73M 10-K · filed 2019-02-26 | |
| 2015-12-31 | -$2.11M 10-K · filed 2018-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |